by jennifer@theshareholdercommons.com | Mar 2, 2022 | Category1
Johnson & Johnson sought to exclude our proposal asking for a report on the costs it externalizes by limiting access to its COVID-19 vaccine technology, and how its diversified shareholders absorb those costs. The company argued the proposal violated U.S.... by jennifer@theshareholdercommons.com | Jan 11, 2022 | Category1
Let’s face it: 2021 brought plenty of disappointments. The pandemic ground on, democratic ideals appeared to be in retreat around the world, and the planet continued to accelerate toward and even past critical boundaries. But if we look upstream, 2021 also provided...